newsfilter
← Latest News
Business Wire·

Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics' RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients

Peer-reviewed study finds standard HER2 IHC testing shows limited predictive value for T-DXd while Ignite's platform — the only commercially available multiplex assay in the study—demonstrates predictive value for